This is particularlythe case in prostate cancer, where AR is the driving nuclear receptor andconsequently, substantial parallels exist between AR-mediated prostate cancerdevelopment in men and ER activity in breast cancer in women. This evidence concerns the gene AR and breast carcinoma.